Key result
Outpatient SGLT2i prescriptions reach ~20% after cardiac decompensation, but maximum HF doses remain rare.
Why the study?
The study analyzed outpatient prescription and dosing of basic pharmacotherapy at the end of 2022 in patients previously hospitalized for cardiac decompensation.
Does outpatient care improve the prescription rates and dosages of guideline-directed medical therapy compared to hospital discharge in patients with heart failure?
Observational (n=975)
No
Does outpatient care improve the prescription rates and dosages of guideline-directed medical therapy compared to hospital discharge in patients with heart failure?
Absolute Event Rate: 20.1% vs 0.7%
p-value: p=<0.0001
Despite some improvements in the prescription of newer heart failure therapies like SGLT2 inhibitors and ARNI in outpatient care, significant gaps remain in achieving guideline-directed medical therapy and target dosages.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Orct et al. (2024) conducted an observational in Chronic heart failure (n=975). Outpatient care vs. Hospital discharge was evaluated on Prescription rate of SGLT2 inhibitors (p=<0.0001). In patients hospitalized for cardiac decompensation, outpatient prescription of SGLT2 inhibitors increased from 0.7% at discharge to 20.1%, though maximum recommended doses of heart failure therapies were rarely achieved.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: